Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma

NCT06924424 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06924424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06924424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
March 1, 2025
Completion date
June 30, 2027
Enrollment
105 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, neoplasms